Device Trial Radar · NCT07176416
Effective Phaco Time and Endothelial Cell Loss When Using Veritas
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Oct 3, 2025
Primary completion
May 19, 2026
Study completion May 19, 2026
Sponsor
- Lead sponsor
- Aloha Vision ConsultantsAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Sengi
- First posted
- Sep 16, 2025
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a single center, prospective study of cumulative dissipated energy and endothelial cells loss per phacoemulsification procedure after successful cataract surgery. Subjects will be assessed 3 months postoperatively at a single visit. Clinical evaluations will include central corneal thickness, specular microscopy, as well as measurement of visual acuities at distance.
Conditions
- Cataract
Interventions
Veritas Vision SystemDevice
Veritas Vision System
Primary outcomes
What the sponsor says the trial is designed to measure.
- Effective phaco time per phacoemulsification procedureTime frame: Surgery (Day 0)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Aloha Vision Consultants
‘Aiea, Hawaii
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.